Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 May;97(5):e70378.
doi: 10.1002/jmv.70378.

Human Cytomegalovirus Virion-Associated mRNA as a Marker of Productive Infection in Immunocompromised Patients

Federica Giardina  1 , Stefania Paolucci  2 , Dalila Mele  2 , Omar Mura  2 , Marina Ramus  2 , José Camilla Sammartino  1 , Piera d'Angelo  2 , Antonino Maria Guglielmo Pitrolo  2 , Giulia Campanini  2 , Eleonora Francesca Pattonieri  3 , Teresa Rampino  3   4 , Marilena Gregorini  3   4 , Francesca Compagno  5 , Domenica Federica Briganti  6 , Elena Seminari  7 , Nicola Polverelli  8 , Irene Cassaniti  1   2 , Daniele Lilleri  1 , Fausto Baldanti  1   2
Affiliations

Human Cytomegalovirus Virion-Associated mRNA as a Marker of Productive Infection in Immunocompromised Patients

Federica Giardina et al. J Med Virol. 2025 May.

Abstract

Human Cytomegalovirus (HCMV) transcripts (including UL21.5 mRNA) have been found to be packaged in virions, and their detection in plasma may indicate the presence of infectious viral particles. The objective of this study was to verify whether UL21.5 mRNA detected in the plasma was indeed encapsulated in viral particles, representing an indirect marker of active replication. To distinguish between virion-packaged and free-floating RNA, plasma samples from 22 immunocompromised patients were tested before and after ribonuclease (RNAse) digestion. UL21.5 mRNA was detected 1-2 weeks before preemptive therapy administration in 20 episodes (from 18 patients) of clinically significant DNAemia, while it was undetectable in three of the four patients with transient, self-resolving DNAemia. After RNAse digestion, UL21.5 mRNA was still detectable, with a median reduction of 0.1 (IQR: 0-0.3) Log10. Concentrations of UL21.5 mRNA in plasma correlated significantly with HCMV DNA in whole blood or plasma (R = 0.67), and 75% of samples positive for UL21.5 mRNA had HCMV DNA concentrations above 104 copies/mL blood or 103 copies/mL plasma. Moreover, UL21.5 mRNA was positive in patients who developed HCMV infection resistant to letermovir or maribavir, whereas it was undetectable in the plasma of patients with transient self-resolving DNAemia blips during letermovir prophylaxis (not associated with drug-resistance). HCMV UL21.5 mRNA in plasma is virion-associated and represents a marker for productive HCMV infection. The determination of UL21.5 mRNA could improve current strategies for the management of HCMV infection in immunocompromised patients.

Keywords: human cytomegalovirus; immunocompromised patients; mRNA; transplant recipients; virion.

PubMed Disclaimer

References

    1. J. Piret and G. Boivin, “Clinical Development of Letermovir and Maribavir: Overview of Human Cytomegalovirus Drug Resistance,” Antiviral Research 163 (2019): 91–105, https://doi.org/10.1016/j.antiviral.2019.01.011.
    1. F. M. Marty, P. Ljungman, R. F. Chemaly, et al., “Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic‐Cell Transplantation,” New England Journal of Medicine 377, no. 25 (2017): 2433–2444, https://doi.org/10.1056/NEJMoa1706640.
    1. I. Cassaniti, A. A. Colombo, P. Bernasconi, et al., “Positive HCMV DNAemia in Stem Cell Recipients Undergoing Letermovir Prophylaxis Is Expression of Abortive Infection,” American Journal of Transplantation 21, no. 4 (2021): 1622–1628, https://doi.org/10.1111/ajt.16450.
    1. Y. Tong, X. L. Pang, C. Mabilangan, and J. K. Preiksaitis, “Determination of the Biological Form of Human Cytomegalovirus DNA in the Plasma of Solid‐Organ Transplant Recipients,” Journal of Infectious Diseases 215, no. 7 (2017): 1094–1101, https://doi.org/10.1093/infdis/jix069.
    1. G. Gerna, F. Baldanti, D. Lilleri, et al., “Human Cytomegalovirus pp67 mRNAemia Versus pp65 Antigenemia for Guiding Preemptive Therapy in Heart and Lung Transplant Recipients: A Prospective, Randomized, Controlled, Open‐Label Trial,” Transplantation 75, no. 7 (2003): 1012–1019, https://doi.org/10.1097/01.TP.0000057239.32192.B9.